Journals / Tüberküloz ve Toraks / 2018 / Cilt: 66 - Sayı: 3

General features of patients with Pulmonary Langerhans Cell Histiocytosis followed in our instution

Pages
205–211
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It is essential to quit smoking in therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Pulmonary Langerhans Cell Histiocytosis (PLCH) is a rare disease affecting young smokers.
📊
Key Findings & Data:It is more common betweenthe ages of 20-40 and equals the male/female ratio.
💡
Conclusion & Impact:It is essential to quit smoking in therapy.
🔬Design:Research Article
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Abstract

Introduction: Pulmonary Langerhans Cell Histiocytosis (PLCH) is a rare disease affecting young smokers. It is more common betweenthe ages of 20-40 and equals the male/female ratio. Lung biopsy is the most useful methods for diagnosis. The first treatment is to quitsmoking. Corticosteroids or chemotherapeutic agents can be used in severe progressive cases despite of quiting smoking. The patientswith PLCH followed in our clinic were assessed with general clinical features in the light of the literature.Materials and Methods: We retrospectively evaluated patients with PLCH in our clinic between January 1999 and June 2017.Results: The female and male distribution of the 21 patients was 11/10. The average age was 35.04 ± 11.78 years. All patients wereactive smokers at the time of admission. The most common symptom was dyspnea. The most common finding in the pulmonaryfunction tests was obstructive ventilatory defect. The DLCO value of the 70% patient in the carbonmonooxid diffusion test was below80%. The most common pathologic findings detected in high-resolution chest tomography (HRCT) were cystic lesions involvingbilateral upper and middle areas. There were 3 (14%) patients with pneumothorax at the time of admission and 6 (28.5%) patientswith pneumothorax history before. The most common diagnostic method was open lung biopsy. All the patients quit cigarette afterthe diagnosis. There were 6 patients using steroid therapy, 1 patient receiving steroid and bosentan therapy, and 1 patient madepleurectomy due to recurrent pneumothorax. Lung transplantation was done to patient who received combined bosentan treatmentwith steroids.Conclusion: PLCH is a rare disease and should be considered inyoung, smokers with spontaneous pneumothorax and cystic lungdisease in the differential diagnosis. As more diffusions are affectedin patients, respiratory functions for follow-up should be evaluatedwith diffusion tests. It is essential to quit smoking in therapy.

🔖

Cite This Article

ACAT, M., ÇETİNKAYA, E., TANRIVERDİ, E., DEMİRKOL, B., ÖZGÜL, M. A., YILDIRIM, B. Z., CHOUSEİN, E. G. U., TURAN, D. (2022). General features of patients with Pulmonary Langerhans Cell Histiocytosis followed in our instution. Tüberküloz ve Toraks, Cilt: 66 - Sayı: 3, 205–211. https://ajindex.com/articles/618441

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Vassallo R, Harari S, Tazi A. Current understanding and management of pulmonary Langerhans cell histiocytosis. Thorax 2017;72:937-45.
  2. Roden AC, Hu X, Kip S, Parrilla Castellar ER, Rumilla KM, Vrana JA, et al. BRAF V600E expression in Langerhans cell histiocytosis: clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases. Am J Surg Pathol 2014;38:548-51.
  3. Kalchiem-Dekel O, Paulk A, Kligerman SJ, Burke AP, Shah NG, Renee K, et al. Development of pulmonary Langerhans cell histiocytosis in a patient with established adenocarcinoma of the lung. J Thorac Dis 2017;9:E1079-E1083. Yousem SA, Dacic S, Nikiforov YE, Nikiforova M. Pulmonary Langerhans cell histiocytosis: profiling of multifocal tumors using next-generation sequencing identifies concordant occurrence of BRAF V600E mutations. Chest 2013;143:1679-84.
  4. Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, American society of clinical oncology, and college of American pathologists. J Mol Diagn 2017;19:4-23.
  5. Park S, Lee EJ. Diagnosis and treatment of cystic lung disease. Korean J Intern Med 2017;32:229-38.
  6. Elia D, Torre O, Cassandro R, Caminati A, Harari S. Pulmonary Langerhans cell histiocytosis: a comprehensive analysis of 40 patients and literature review. Eur J Intern Med 2015;26:351-6.
  7. Girschikofsky M, Arico M, Castillo D, Chu A, Doberauer C, Fichter J, et al. Management of adult patients with Langerhans cell histiocytosis: recommendations from an expert panel on behalf of Euro-Histio-Net. Orphanet J Rare Dis 2013;8:72. Radzikowska E. Pulmonary Langerhans’ cell histiocytosis in adults. Adv Respir Med 2017;85:277-89.
  8. Baldi BG, Carvalho CB, Dias OM, Marchiori E, Hochhegger B. Diffuse cystic lung diseases: differential diagnosis. J Bras Pneumol 2017;43:140-9. Trotman-Dickenson B. Cystic lung disease: achieving a radiologic diagnosis. Eur J Radiol 2014;83:39-46.
  9. Earlam K, Souza CA, Glikstein R, Gomes MM, Pakhalé S. Pulmonary langerhans cell histiocytosis and diabetes insipidus in a young smoker. Can Respir J 2016;2016:3740902. Mello RAF, Tanos JW, Mello MBN, Marchiori E. Multisystemic langerhans cell histiocytosis with advanced lung involvement. J Radiol Case Rep 2012;6:22-8.
  10. Altay MA, Sindel A, Özalp Ö, Kocabalkan B, Özbudak İH, Erdem R, et al. langerhans cell histiocytosis: a diagnostic challenge i